CCM
IMCR icon

Catalio Capital Management’s Immunocore IMCR Stock Holding History

Catalio Capital Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.7M Buy
148,045
+63,693
+76% +$1.88M 0.88% 31
2026
Q1 		$2.54M Buy
+84,352
New +$2.73M 0.53% 35

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Catalio Capital Management's IMCR Position: Q2 2026 in Review

Catalio Capital Management increased its Immunocore (IMCR) stake by 76% in Q2 2026, buying an estimated $1.88M and bringing the position to 148,045 shares worth $4.7M. The position accounts for 0.88% of the portfolio, ranked #31.

Catalio Capital Management first reported a position in IMCR in Q1 2026 and has held it in 2 quarters since. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • Catalio Capital Management held 148,045 shares of Immunocore worth $4.7M as of Q2 2026.
  • Catalio Capital Management bought 63,693 Immunocore shares in Q2 2026, an estimated $1.88M.
  • Immunocore made up 0.88% of Catalio Capital Management's portfolio in Q2 2026, its #31 holding.
  • Catalio Capital Management first reported a position in Immunocore in Q1 2026 and has held it in 2 quarters since.
  • 136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Catalio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.